Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the ...

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Tiziana Life Sciences ...

Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential ...

Topline results were announced from a phase 3 trial investigating intranasal carbetocin for the treatment of hyperphagia in Prader-Willi syndrome.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

A new study led by Mass General Brigham investigators compared the effects of repeated intravenous (IV) ketamine and ...

Acadia Pharmaceuticals said on Wednesday it will not proceed further with the development of its intranasal therapy to treat a rare genetic condition after it failed to meet the main goal in a ...

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.

The Food and Drug Administration (FDA) has approved Enbumyst ™, a nasal spray formulation of bumetanide, for the treatment of edema associated with congestive heart failure (CHF), and hepatic and ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501.

Acadia Pharmaceuticals shares were halted at $23.80 in premarket trading after the company said top-line results from its Phase 3 trial for ACP-101 missed its primary endpoint.

This spray formulation of bumetanide demonstrated a 33% faster absorption rate than oral bumetanide, according to clinical ...